16 Aug 2018 11:03
INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Portfolio Update as at 31 July 2018
Net Assets | £251m |
Net Assets per share | 670p |
Share price | 668p |
Total value of unquoted investments | £28m |
Total number of portfolio companies | 74 |
Dividend | 4% of NAV per annum |
Top Ten Quoted Investments
Company Name | % NAV |
Celgene | 6.9 |
Illumina | 5.1 |
Vertex | 4.4 |
Genmab | 3.9 |
Exelixis | 3.7 |
Regeneron | 3.5 |
Morphosys | 3.4 |
Alexion | 3.3 |
Neurocrine | 3.3 |
Array | 3.2 |
| ----------- |
Total | 40.7 |
Geographical Allocation | % NAV |
US & Canada | 86 |
Europe | 14 |
| ----------- |
Total | 100 |
Quoted/Unquoted Allocation | % NAV |
Quoted | 89 |
Unquoted | 11 |
| ----------- |
Total | 100 |
NAV % Market Cap | % NAV |
Large Cap >USD10BN | 35 |
Mid Cap =USD1-10BN | 41 |
Small Cap | 24 |
| ----------- |
Total | 100 |
NAV % by Therapeutic Areas | % NAV |
Oncology | 47 |
CNS | 13 |
Rare diseases | 14 |
Ophthalmology | 7 |
Infectious Diseases | 3 |
Inflammation | 2 |
Metabolic | 2 |
Medtech | 2 |
Other | 10 |
| ----------- |
Total | 100 |
BNP Paribas Secretarial Services Limited
Company Secretary
16 AUGUST 2018